In this hyper-noisy world in which we now live, buzz can be both good and bad. Ask any drugmaker. The quest for a higher profile is balanced against mitigating unwanted attention. Of course, there is reason to be interested in both. And so Semantelli, a market research firm that tracks social media in the pharma world, is providing some snapshots on a regular basis. In the latest installment, the firm looked for drugmakers that generated significant mention on Tweets, blogs, Facebook and other venues. But rather than simply list those that garnered the most attention – which would likely yield several obvious candidates time and again – we chose to find those with the biggest change from the prior week.
